

2nd edition

Unmet challenges in high risk hematological malignancies: from benchside to clinical practice

Turin, September 13-14, 2021

Starhotels Majestic

Scientific board:

Marco Ladetto (Alessandria)

Umberto Vitolo (Candiolo-TO)



AUSPICES

UNIVERSITÀ DEL PIEMONTE ORIENTALE

ISTITUTO DI CANDIOLO - FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA - IRCCS

AZIENDA OSPEDALIERA DI ALESSANDRIA SANTI ANTONIO E BIAGIO E CESARE ARRIGO

UNIVERSITÀ DI TORINO

AZIENDA OSPEDALIERO-UNIVERSITARIA

Città della Salute e della Scienza di Torino - Presidio Ospedaliero Le Molinette

FIL - Fondazione Italiana Linfomi

GITMO - Gruppo Italiano per il Trapianto di Midollo Osseo,
cellule staminali emopoietiche e terapia cellulare

SIE - Società Italiana di Ematologia

SIES - Società Italiana di Ematologia Sperimentale

RETE ONCOLOGICA DEL PIEMONTE E DELLA VALLE D'AOSTA

FACULTY

| | | | | | |
|-----------------------|---------------------|---------------------|--------------------|-------------------|-------------------------|
| Emanuele | Angelucci | Genoa, Italy | Alessandra | Larocca | Turin, Italy |
| Stephen M. | Ansell | Rochester, USA | Maurizio | Martelli | Rome, Italy |
| Hervé | Avet Loiseau | Toulouse, France | Massimo | Massaia | Cuneo, Italy |
| Monica | Balzarotti | Rozzano (MI), Italy | Grzegorz S. | Nowakowski | Rochester, USA |
| Renato | Bassan | Mestre (VE), Italy | Owen A. | O'Connor | Charlottesville, USA |
| Mario | Boccardo | Turin, Italy | Fabrizio | Pane | Naples, Italy |
| Alan K. | Burnett | Glasgow, UK | Stefano A. | Pileri | Milan, Italy |
| Angelo Michele | Carella | Genoa, Italy | Christiane | Pott | Kiel, Germany |
| Annalisa | Chiappella | Milan, Italy | Patrizia | Pregno | Turin, Italy |
| Daniela | Cilloni | Turin, Italy | Alessandro | Rambaldi | Bergamo, Italy |
| Antonio | Cuneo | Ferrara, Italy | Luigi | Rigacci | Rome, Italy |
| Brunangelo | Falini | Perugia, Italy | Giuseppe | Saglio | Turin, Italy |
| Simone | Ferrero | Turin, Italy | Valeria | Santini | Florence, Italy |
| Robin | Foà | Rome, Italy | Stephen J. | Schuster | Philadelphia, USA |
| Nathan H. | Fowler | Houston, USA | Michele | Spina | Aviano (PN), Italy |
| Gianluca | Gaidano | Novara, Italy | Enrico | Tiacci | Perugia, Italy |
| Paolo | Ghia | Milan, Italy | Jan | Trka | Prague, Czech Republic |
| John | Gribben | London, UK | Adriano | Venditti | Rome, Italy |
| Paola | Guglielmelli | Florence, Italy | Carlo | Visco | Verona, Italy |
| Olivier | Hermine | Paris, France | Umberto | Vitolo | Candiolo (TO), Italy |
| Wolfgang | Hiddemann | Munich, Germany | Elena | Zamagni | Bologna, Italy |
| Peter | Hillmen | Leeds, UK | Emanuele | Zucca | Bellinzona, Switzerland |
| Martin | Hutchings | Copenhagen, Denmark | | | |
| Nicolaus | Kroeger | Hamburg, Germany | | | |
| Marco | Ladetto | Alessandria, Italy | | | |

09.00 **Welcome and introduction**

M. Ladetto, U. Vitolo and Scientific Authorities

09.30-11.00 **Hodgkin Lymphoma and T-cell Lymphoma**

Chairmen: M. Spina, U. Vitolo

09.30 Genetics and biology of classical Hodgkin Lymphoma: clinical implications

E. Tiacci

09.50 How I treat high risk Hodgkin Lymphoma

S.M. Ansell

10.10 Histopathology and molecular biology of T-cell Lymphoma

S.A. Pileri

10.30 How I treat high risk T-cell Lymphomas

O.A. O'Connor

10.50 Panel Discussion

11.00-11.30 **LECTURE I**

Chairman: M. Ladetto

Optimizing outcomes for CD19-directed CAR-T cell therapy in refractory B-cell lymphomas

S.J. Schuster

11.30-12.45 **Mantle Cell Lymphoma**

Chairmen: M. Ladetto, M. Martelli

11.30 Biological identification of high risk Mantle Cell Lymphoma

C. Pott

11.50 How I treat high risk Mantle Cell Lymphoma in first line

O. Hermine

12.10 How I treat relapsed/refractory Mantle Cell Lymphoma

C. Visco

12.30 Panel Discussion

12.45-14.00 *Lunch*

14.00-14.30 LECTURE II

Chairman: *U. Vitolo*

Impact of Lugano conferences in the lymphoma research

E. Zucca

14.30-16.00 Diffuse large B-Cell Lymphoma

Chairmen: *M. Balzarotti, U. Vitolo*

14.30 Biological identification of high risk DLBCL

G. Gaidano

14.50 How I treat high risk DLBCL in first line

A. Chiappella

15.10 How I treat DLBCL in relapse

G.S. Nowakowski

15.30 Novel antibodies in aggressive lymphomas

M. Hutchings

15.50 Panel Discussion

16.00-17.10 Follicular Lymphoma

Chairmen: *M.Ladetto, L. Rigacci*

16.00 Biology of high risk Follicular Lymphoma

S. Ferrero

16.20 How I treat high risk Follicular Lymphoma in first line

W. Hiddemann

16.40 How I treat relapsed/refractory Follicular Lymphoma

N.H. Fowler

17.00 Panel Discussion

17.10-18.20 Chronic Lymphocytic Leukemia

Chairmen: *A. Cuneo, P. Ghia*

17.10 Biology of high risk Chronic Lymphocytic Leukemia

M. Massaia

17.30 Defining high risk Chronic Lymphocytic Leukemia in 2021 from the clinician's perspective

J. Gribben

17.50 How I treat relapsed/refractory Chronic Lymphocytic Leukemia

P. Hillmen

5 18.10 Panel Discussion

9.15-10.25 Multiple Myeloma

Chairmen: M. Boccadoro, M. Massaia

09.15 Biology of high risk Multiple Myeloma
H. Avet-Loiseau

09.35 How I treat young high risk Multiple Myeloma
E. Zamagni

09.55 How I treat elderly high risk Multiple Myeloma
A. Larocca

10.15 Panel Discussion

10.30-11.00 LECTURE III

Chairman: G. Saglio

Beyond 3+7 in Acute Myelogenous Leukemia
A.K. Burnett

11.00-12.10 Myeloproliferative Disorders

Chairmen: A.M. Carella, G. Saglio

11.00 Biology of high risk myeloproliferative disorders
P. Guglielmelli

11.20 How I treat high risk Chronic Myeloid Leukemia
P. Pregnò

11.40 How I treat high risk myeloproliferative neoplasms
D. Cilloni

12.00 Panel Discussion

12.10-13.10 *Lunch*

13.10-14.20 Acute Lymphoblastic Leukemia and Transplantation

Chairmen: R. Foà, A. Rambaldi

- 13.10 Biology of High Risk Acute Lymphoblastic Leukemia
J. Trka
- 13.30 How I treat high risk Acute Lymphoblastic Leukemia in first line
R. Bassan
- 13.50 Allogeneic transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes
N. Kroeger
- 14.10 Panel Discussion

14.20-15.30 Acute Myeloblastic Leukemia and Myelodysplastic Syndrome

Chairmen: E. Angelucci, F. Pane

- 14.20 Genomic identification of high risk Acute Myeloid Leukemia
B. Falini
- 14.40 How I treat high risk Myelodysplastic Syndromes
V. Santini
- 15.00 How I treat elderly Acute Myeloid Leukemia patients
A. Venditti
- 15.20 Panel Discussion
- 15.30-15.45 **Closing remarks**
M. Ladetto, U. Vitolo

With an unrestricted educational grant of:

abbvie

astellas

Karyopharm[®]
Therapeutics

AstraZeneca

BeiGene

Celgene | Bristol Myers Squibb[®]
Company

gsk

Roche

AMGEN[®]

GILEAD

Incyte | SOLVE
ON.

janssen Oncology
PHARMACEUTICAL COMPANY OF Johnson & Johnson

NOVARTIS

Pfizer

SANDOZ A Novartis
Division

GENERAL INFORMATION

MEETING VENUE

Starhotels Majestic

Corso Vittorio Emanuele II, 54
10123 Torino, Italy
Tel. +39 011 539153

ITALIAN CME CREDITS

An Italian CME application has been submitted as follows:

- Provider Studio ER Congressi SRL: ID 828- 282393.
- No. 9,1 CME credits for Physicians (Haematology, Oncology, Internal Medicine) and Biologists.
- Educational objective: "linee guida-protocolli-procedure".

OFFICIAL LANGUAGE

English

BADGE AND CERTIFICATE OF ATTENDANCE

All registered participants and speakers will be given a badge which must be worn in order to be admitted to the scientific sessions. A certificate will be given to all participants at the end of the meeting.



The organization is proud to compensate its greenhouse gas emissions investing in the carbon offset project: "Mytrah Wind Power".

SCIENTIFIC BOARD

Marco Ladetto MD

Associate Professor in Haematology
University of Eastern Piedmont Amedeo Avogadro
S.S. Antonio and Biagio and Cesaro Arrigo Hospital
Via Venezia, 16 - 15121 Alessandria, Italy

Umberto Vitolo MD

Hematology Consultant
Candiolo Cancer Institute - FPO-IRCCS
Strada Provinciale, 142 - 10060 Candiolo (TO), Italy

SCIENTIFIC COMMITTEE

Prof. Mario Boccadoro (Turin)

Prof. Gianluca Gaidano (Novara)

Prof. Massimo Massaia (Cuneo)

Prof. Giuseppe Saglio (Orbassano - TO)

ORGANIZING SECRETARIAT

Studio E.R. Congressi

Via De' Poeti, 1/7 - 40124 Bologna, Italy
Phone +39 051 4210559 - Fax +39 051 4210174
E-mail: ercongressi@ercongressi.it
www.ercongressi.it